AN2 Therapeutics, Inc.
About AN2 Therapeutics, Inc.
AN2 Therapeutics (AN2) is a biopharmaceutical company focused on developing novel medicines for patients with rare, orphan infectious diseases that represent significant unmet needs. Founded by a team of experienced industry leaders in infectious diseases drug research and development, we strive to provide patients with treatments that will restore their health and enable them to live productive lives. AN2 is a mission-driven company with a passion for improving global public health and a vision to accelerate development of novel medicines to treat serious infectious diseases and save lives worldwide
8 articles with AN2 Therapeutics, Inc.
-
AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
5/10/2022
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2022.
-
AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors
5/9/2022
AN2 Therapeutics, Inc. today announced the appointment of Maggie FitzPatrick to its Board of Directors.
-
AN2 Therapeutics Appoints Dr. Mel Spigelman, M.D. to its Board of Directors
3/16/2022
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, announced the appointment of Dr. Mel Spigelman, M.D., to its Board of Directors.
-
AN2 Therapeutics Announces Epetraborole Granted Orphan Drug Designation in the U.S. for the Treatment of Infections Caused by Non-Tuberculous Mycobacteria
2/16/2022
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to epetraborole for the treatment of infections caused by non-tuberculous mycobacteria (NTM).
-
AN2 Therapeutics Reports Phase 1b Data for Oral Epetraborole
2/10/2022
AN2 Therapeutics, Inc., today announced topline results from its Phase 1b dose-ranging study of oral epetraborole. AN2 Therapeutics is developing epetraborole.
-
AN2 Therapeutics Provides Regulatory Update and Plan to Initiate Clinical Development for Epetraborole Targeting NTM Lung Disease
1/20/2022
AN2 Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) cleared the Company's Investigational New Drug (IND) application for epetraborole, a once-daily, orally administered investigational treatment for patients with non-tuberculous mycobacterial (NTM) lung disease in December.
-
AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program
1/7/2022
AN2 Therapeutics, Inc. today announced several significant strides in the company's development over the past year.
-
California-based AN2 Therapeutics secured $80 million in a Series B funding round to help advance its novel nontuberculous mycobacterial lung disease program.